Axicabtagene ciloleucel clinical trials

Studies by the year they started

28 studies that test it; most in 2023 (4)

Who runs them

Industry 12 · Other 16

Kite, A Gilead Company (11) · Ruijin Hospital (2) · M.D. Anderson Cancer Center (2) · Dana-Farber Cancer Institute (1) · The Lymphoma Academic Research Organisation (1) · Masonic Cancer Center, University of Minnesota (1) · NeoImmuneTech (1) · Vanderbilt-Ingram Cancer Center (1)

Often tested with

Tested in the same studies.

Tisagenlecleucel (3) · Fludarabine (3) · Cyclophosphamide (3) · Lisocabtagene maraleucel (3) · Brexucabtagene autoleucel (1) · Idecabtagene vicleucel (1) · Efineptakin alfa (1) · Atezolizumab (1)

Studies

Open first, then newest update. How each study uses axicabtagene ciloleucel is read from its arms, and is right about nine times in ten.

Testing it · 28

• Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 2SWOG Cancer Research NetworkNCT05633615Written as Axicabtagene Ciloleucel
• Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyRecruitingPhase 3Kite, A Gilead CompanyNCT07479797Written as Axicabtagene Ciloleucel
• A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06213311Written as Axi-cel
• A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06043323Written as Axicabtagene Ciloleucel
• Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaRecruitingPhase 1AIDS Malignancy ConsortiumNCT05077527Written as Axicabtagene Ciloleucel
• CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.RecruitingPhase 2Zhejiang Cancer HospitalNCT07538635Written as Axicabtagene Ciloleucel
• Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T CellsRecruitingPhase 2City of Hope Medical CenterNCT07042438Written as Axicabtagene Ciloleucel
• Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaRecruitingPhase 2Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaNCT07254754Written as Axicabtagene Ciloleucel
• Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-CelRecruitingPhase 1Stanford UniversityNCT05794958Written as Axicabtagene Ciloleucel
• Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell LymphomaNot yet recruitingNot applicableRuijin HospitalNCT06935136Written as Axicabtagene Ciloleucel
• Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular LymphomaRecruitingPhase 2The First Affiliated Hospital of Xiamen UniversityNCT06826118Written as Axicabtagene Ciloleucel
• Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell LymphomaRecruitingPhase 4Zhengzhou UniversityNCT06609304Written as Axicabtagene Ciloleucel
• Axi-cel in CNS LymphomaActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT04608487Written as Axicabtagene Ciloleucel
• Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedPhase 1NeoImmuneTechNCT05075603Written as Axicabtagene ciloleucel
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell LymphomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT05605899Written as Axicabtagene Ciloleucel
• Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell TransplantationActive, not recruitingPhase 2The Lymphoma Academic Research OrganisationNCT04531046Written as axicabtagene ciloleucel
• Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell LymphomaCompletedPhase 2Kite, A Gilead CompanyNCT05459571Written as Axicabtagene Ciloleucel
• MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03642626Written as YESCARTA
• A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin LymphomaCompletedPhase 2Kite, A Gilead CompanyNCT03105336Written as Axicabtagene ciloleucel
• Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedPhase 3Kite, A Gilead CompanyNCT03391466Written as Axicabtagene Ciloleucel

See all 28 studies that test axicabtagene ciloleucel →

Codes

What other systems call axicabtagene ciloleucel · ClinicalTrials.gg INT001010

• MeSH (NLM) C000629083axicabtagene ciloleucelConfirmed ClinicalTrials.gov, NLM
• UNII (FDA) U2I8T43Y7RAXICABTAGENE CILOLEUCELConfirmed FDA, NLM, Wikidata
• RxNorm 1987398Confirmed FDA, Wikidata
• Wikidata Q30314851axicabtagene ciloleucelConfirmed FDA, NLM, Wikidata
• NCI Thesaurus C120309Axicabtagene CiloleucelOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.